Brightsurf Science News & Current Events

June 22, 2008
Leukemia drug could save lives of stroke patients
Published today in Nature Medicine, investigators from the Stockholm Branch of the Ludwig Institute for Cancer Research and University of Michigan Medical School show that toxicity associated with tPA, the most effective treatment currently available to stroke patients, might be overcome if combined with the leukemia drug, imatinib.

Drug reverses mental retardation caused by genetic disorder
A new UCLA study shows that the FDA-approved drug rapamycin reverses mental retardation in mice with a genetic disease called tuberous sclerosis complex.

New source of heart stem cells discovered
Researchers at Children's Hospital Boston are continuing to document the heart's earliest origins.

Stroke study reveals key target for improving treatment and suggests that Gleevec may help
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke, but bleeding risks and a limited time window for treatment have held it back.

DNA study unlocks mystery to diverse traits in dogs
In the cover story of tomorrow's edition of the science journal Genetics, research reveals locations in a dog's DNA that contain genes that scientists believe contribute to differences in body and skull shape, weight, fur color and length -- and possibly even behavior, trainability and longevity.

A plane with wings of glass?
Glass is actually a

CSIRO scientist discovers natural 'invisible' gold
Nanoparticles of gold too small to be seen with the naked eye have been created in laboratories, but up until now, have never been seen in nature.

Understanding the migration of cancer cells
Lamellipodia and filopodia are dynamic surface extensions of the cell which play a pivotal role in cell migration, invasion and wound healing. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to